Zepp Health Corporation
NYSE:ZEPPConsumer Electronics
-$0.03 today
- Market cap
- $50.84M
- Beta
- 1.78
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$282.07
Volume 0.04M
Average 0.13M
ZEPP EBITDA Margin
EBITDA as a percentage of revenue.
Zepp Health CorporationNYSE: ZEPP
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -34.5%
EBITDA Margin was -34.5% in Q1 FY2026, up 12.0 pp from a year earlier. On a trailing-twelve-month basis it was -10.6%, up 20.9 pp year over year. Over 3 fiscal years it narrowed by 4.3 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 2.6% for the fiscal year ending Dec 2026, up from -10.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -34.5%-25.9 pp QoQ
- Last fiscal yearDec 2025
- -10.5%+15.4 pp YoY
- LTMMar 2026
- -10.6%+20.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.0 pp | — | — |
| 1 year | +15.4 pp | +13.1 pp | -2.2 pp |
| 3 years | -4.3 pp | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -10.5%
- Year-over-year change
- +15.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -10.5% | +15.4pp |
| FY2024 | 2024-12-31 | -25.9% | -20.2pp |
| FY2023 | 2023-12-31 | -5.7% | +0.5pp |
| FY2022 | 2022-12-31 | -6.2% | -9.5pp |
| FY2021 | 2021-12-31 | 3.3% | — |
EBITDA Margin vs competitors
How ZEPP compares with its peers on the latest reported figures
- ZEPP's LTM Mar 2026 EBITDA Margin of -10.6% is the 5th highest of the 8 companies compared; the peer median is -7.1%.
- Its year-over-year change of +20.9 pp is the 3rd highest of 8, against a peer median of -0.7 pp.
- Over three fiscal years its change of -4.3 pp compares with a peer median of -5.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 143.7% | +634.0 pp | +156.7 pp | |
| LTM Mar 2026 | -1.1% | +1.1 pp | -12.7 pp | |
| LTM Mar 2026 | -6.0% | -0.7 pp | -5.2 pp | |
| LTM Mar 2026 | -7.1% | -12.2 pp | -0.1 pp | |
| LTM Mar 2026 | -10.6% | +20.9 pp | -4.3 pp | |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | -39.6% | +59.9 pp | -61.3 pp |
| FY2025 | -158.6% | -47.6 pp | -200.6 pp | |
| LTM Mar 2026 | -375.1% | -123.7 pp | +71.2 pp | |
| Peer median (excluding ZEPP) | -7.1% | -0.7 pp | -5.2 pp | |
Competitors are the stored peer set for ZEPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.17B | 4.22B | 2.5B | 1.33B | 1.82B |
| Cost of Revenue | 4.88B | 3.4B | 1.84B | 820.57M | 1.1B |
| Gross Profit | 1.29B | 817.22M | 653.7M | 512.88M | 711.63M |
| Gross Margin | 20.9% | 19.4% | 26.2% | 38.5% | 39.2% |
| Research & Development | 508.41M | 526.2M | 364.53M | 337.07M | 317.73M |
| Selling, General & Admin | 687.6M | 708.46M | 504.69M | 520.85M | 582.64M |
| Operating Expenses | 1.2B | 1.23B | 869.22M | 857.92M | 916.56M |
| Depreciation & Amortization | 51.21M | 59.65M | 54.43M | 36.64M | 31.71M |
| EBITDA | 200.8M | (261.43M) | (142.88M) | (345.66M) | (191.48M) |
| EBITDA Margin | 3.3% | -6.2% | -5.7% | -25.9% | -10.5% |
| Operating Income | 92.73M | (417.45M) | (215.52M) | (345.04M) | (204.93M) |
| Operating Margin | 1.5% | -9.9% | -8.6% | -25.9% | -11.3% |
| Interest Income | 16.47M | 12.55M | 21.86M | 26.81M | 10.7M |
| Interest Expense | 44.3M | 58M | 47.79M | 40.54M | 39.94M |
| Other Income / Expenses | 53.06M | 56.34M | (21.7M) | (108.55M) | (58.2M) |
| Income Before Tax | 145.78M | (361.11M) | (237.22M) | (453.59M) | (263.13M) |
| Pre-Tax Margin | 2.4% | -8.6% | -9.5% | -34.0% | -14.5% |
| Income Tax Expense | 10.61M | (67.03M) | (17.2M) | 99.99M | 17.79M |
| Net Income | 136.02M | (293.37M) | (220.49M) | (554.13M) | (280.92M) |
| Net Margin | 2.2% | -7.0% | -8.8% | -41.6% | -15.5% |
| EPS (Basic) | 1.38 | (2.71) | (1.96) | (34.16) | (283.04) |
| EPS (Diluted) | 1.31 | (2.71) | (1.96) | (34.16) | (283.04) |
| Weighted Avg Shares | 15.76M | 15.39M | 15.2M | 16.18M | 993.87K |
| Weighted Avg Shares (Diluted) | 16.52M | 15.39M | 15.2M | 16.18M | 993.87K |
Zepp Health Corporation
NYSE:ZEPP
Intrinsic Alpha fair value
Locked
Current Price
$3.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.